February 11th 2025
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
Verona Pharma Receives $650M Investment from Oaktree Capital Management and OMERS Life Sciences
May 9th 2024Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.
Industry Business Check: Market Review Rates the Latest Full-Year Outputs
March 13th 2024A look at pharma and biotech financing, M&A, and stock market performance in 2023—and where developments may head next as company executives continue to navigate stormy but perhaps stabilizing waters in the months ahead.